Merck will present data at ESMO 18th WCGC
Notably, compared with those receiving FOLFOX alone, patients in the study receiving Erbitux plus FOLFOX experienced1:
· a bORR of 61.1% (versus 39.5%; odds ratio [OR]: 2.41; p<0.001), which is in line with international studies
· a 31% decrease in the risk of disease progression (hazard ratio [HR]: 0.69; p=0.004); and,
· a 24% reduction in the risk of death (HR: 0.76; p=0.02).
“As a standard-of-care treatment, Erbitux is a strategic priority product for Merck and our aspiration is that patients have optimal access to this drug worldwide,” said Luciano Rossetti, Global Head of Research & Development in the biopharma business of Merck. “We are confident the TAILOR results form a good basis upon which approval could be extended to first-line metastatic colorectal cancer treatment in China.”
The TAILOR study randomized 393 patients from China with RAS wild-type mCRC, and the results demonstrate that adding Erbitux to FOLFOX, as a first-line treatment, significantly improves PFS (median PFS: 9.2 vs 7.4 months) and OS (median OS: 20.7 vs 17.8 months). The safety profile of Erbitux observed in TAILOR is similar to that seen in prior randomized clinical trials, with no unexpected safety findings.
Комментарии